A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population

详细信息    查看全文

• 作者：Chien-Hung Gow^a ; ^b ; ^e ; ¹ ; Min-Shu Hsieh^c ; ¹ ; Shang-Gin Wu^d ; ^e ; ^f ; Jin-Yuan Shih^e ; ^f ; ^{jyshih@ntu.edu.tw}
• 关键词：MET ; MET proto-oncogene ; receptor tyrosine kinase ; METΔ14 ; MET exon 14 skipping ; ADC ; adenocarcinoma ; IHC ; immunohistochemistry ; SCC ; squamous cell carcinoma ; OS ; overall survival
• 刊名：Lung Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：103
• 期：Complete
• 页码：82-89
• 全文大小：2493 K
• 卷排序：103

文摘

We detected METΔ14 and five other major driver mutations in lung cancer patients. METΔ14 mutation can be successfully detected in a one-step RT-PCR using RNA samples. METΔ14 mutation positive samples exhibited a strong cytoplasmic expression of MET. Stage IV METΔ14 positive and driver mutation negative groups have a similar OS. Mutation status was not a major risk factor for OS in advanced lung cancer.